{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:17:18Z","timestamp":1789010238674,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To examine the agreement of different calculated estimated glomerular filtration rate (eGFR) formulas and measured creatinine clearance (CrCI) at the primary diagnosis of muscle-invasive bladder cancer (MIBC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We performed a multicenter analysis of patients with MIBC, treated with cisplatin-based neoadjuvant chemotherapy (NAC) and radical cystectomy (RC), or with RC alone, between 2011 and 2021. Baseline eGFR was computed using 4 calculated serum equations including Cockcroft-Gault (CG), MDRD, CKD-EPI 2009, and race-free CKD-EPI 2021. To examine the association between calculated eGFR and measured CrCI, subgroup analyses were performed among patients in whom measured 24-hour urine CrCl was determined. Cisplatin-ineligibility was defined as CrCI and\/or eGFR\u2005&amp;lt;\u200560 mL\/minute per 1.73 m2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 956 patients, 30.0%, 33.3%, 31.9%, and 27.7% were found to be cisplatin-ineligible by the CG, MDRD, CKD-EPI, and race-free CKD-EPI equations (P\u2005=\u2005.052). The concordance between calculated eGFR formulas was rated substantial (Cohen\u2019s kappa (k): 0.66-0.95). Among the subgroup (n\u2005=\u2005245) with measured CrCl, 37 (15.1%) patients had a CrCI less than 60 mL\/minute. Concordance between measured CrCl and calculated eGFR was poor (\u0138: 0.29-0.40). All calculated eGFR formulas markedly underestimated the measured CrCI. Specifically, 78%-87.5% of patients with a calculated eGFR between 40 and 59 mL\/minute exhibited a measured CrCI\u2005\u2265\u200560 mL\/minute.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Comparing calculated eGFR formulas, similar percentages of patients with MIBC were deemed cisplatin-ineligible. However, a significant number of patients could be upgraded by being cisplatin-fit based on measured CrCI, particularly when the calculated eGFR was falling within the gray range of 40-59 mL\/minute.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae160","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T19:23:19Z","timestamp":1718220199000},"page":"e1511-e1522","source":"Crossref","is-referenced-by-count":11,"title":["Cisplatin eligibility in the neoadjuvant setting of patients with muscle-invasive bladder cancer undergoing radical cystectomy"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5286-9048","authenticated-orcid":false,"given":"Renate","family":"Pichler","sequence":"first","affiliation":[{"name":"Department of Urology, Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck , Innsbruck 6020 ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Fritz","sequence":"additional","affiliation":[{"name":"Institute of Medical Statistics and Informatics, Medical University of Innsbruck , Innsbruck 6020 ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mari","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cadenar","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"von Deimling","sequence":"additional","affiliation":[{"name":"Department of Urology, University Medical Center Hamburg-Eppendorf , Hamburg 20249 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautier","family":"Marcq","sequence":"additional","affiliation":[{"name":"Department of Urology, Claude Huriez Hospital, CHU Lille , Lille 59037 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"del Giudice","sequence":"additional","affiliation":[{"name":"Department of Maternal Infant and Urologic Sciences, \u201cSapienza\u201d University of Rome, Policlinico Umberto I Hospital , Rome 00185 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costantino","family":"Leonardo","sequence":"additional","affiliation":[{"name":"Department of Maternal Infant and Urologic Sciences, \u201cSapienza\u201d University of Rome, Policlinico Umberto I Hospital , Rome 00185 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Bologna","sequence":"additional","affiliation":[{"name":"Department of Maternal Infant and Urologic Sciences, \u201cSapienza\u201d University of Rome, Policlinico Umberto I Hospital , Rome 00185 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 105-8461 Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Tahbaz","sequence":"additional","affiliation":[{"name":"Department of Urology, Charit\u00e9 Universit\u00e4tsmedizin Berlin , Berlin 10117 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[{"name":"Department of Urology, Charit\u00e9 Universit\u00e4tsmedizin Berlin , Berlin 10117 ,","place":["Germany"]},{"name":"Department of Urology, Medical University Vienna , Vienna 1090 ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Klatte","sequence":"additional","affiliation":[{"name":"Department of Urology, Charit\u00e9 Universit\u00e4tsmedizin Berlin , Berlin 10117 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Erber","sequence":"additional","affiliation":[{"name":"Department of Urology, Charit\u00e9 Universit\u00e4tsmedizin Berlin , Berlin 10117 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felizian","family":"Lackner","sequence":"additional","affiliation":[{"name":"Department of Urology, Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck , Innsbruck 6020 ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cambridge , Cambridge CB2 0QQ ,","place":["United Kingdom"]},{"name":"Department of Internal Medicine IV, Medical University of Innsbruck , Innsbruck 6020 ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4401-8248","authenticated-orcid":false,"given":"Andreas","family":"Seeber","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck , Innsbruck 6020 ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"Fisch","sequence":"additional","affiliation":[{"name":"Department of Urology, University Medical Center Hamburg-Eppendorf , Hamburg 20249 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[{"name":"Department of Urology, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University , Milan 20132 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[{"name":"Department of Urology, La Croix du Sud Hospital , 31130 Quint-Fonsegrives ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S","family":"Mertens","sequence":"additional","affiliation":[{"name":"Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital , Amsterdam 1006 ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"issue":"3","key":"2024110817081966400_CIT0001","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"issue":"3","key":"2024110817081966400_CIT0002","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","article-title":"Updated 2016 EAU Guidelines on muscle-invasive and metastatic bladder cancer","volume":"71","author":"Alfred Witjes","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"2024110817081966400_CIT0003","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","author":"Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration","year":"2005","journal-title":"Eur Urol"},{"issue":"5b","key":"2024110817081966400_CIT0004","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1111\/bju.12274","article-title":"Eligibility for neoadjuvant\/adjuvant cisplatin-based chemotherapy among radical cystectomy patients","volume":"113","author":"Thompson","year":"2014","journal-title":"BJU Int"},{"issue":"17","key":"2024110817081966400_CIT0005","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for Cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024110817081966400_CIT0006","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clgc.2011.10.004","article-title":"Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer","volume":"10","author":"Tsao","year":"2012","journal-title":"Clin Genitourin Cancer"},{"issue":"19","key":"2024110817081966400_CIT0007","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.2005.04.3091","article-title":"Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer","volume":"24","author":"Ray","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"2024110817081966400_CIT0008","doi-asserted-by":"crossref","first-page":"793","DOI":"10.6004\/jnccn.2013.0101","article-title":"Optimizing systemic therapy for bladder cancer","volume":"11","author":"Pal","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"2024110817081966400_CIT0009","doi-asserted-by":"crossref","first-page":"e94471","DOI":"10.1371\/journal.pone.0094471","article-title":"CKD-EPI and cockcroft-gault equations identify similar candidates for neoadjuvant chemotherapy in muscle-invasive bladder cancer","volume":"9","author":"Pal","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"2024110817081966400_CIT0010","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41585-020-00404-6","article-title":"Defining cisplatin eligibility in patients with muscle-invasive bladder cancer","volume":"18","author":"Jiang","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"3","key":"2024110817081966400_CIT0011","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","article-title":"A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy","volume":"12","author":"Galsky","year":"2011","journal-title":"Lancet Oncol"},{"issue":"18","key":"2024110817081966400_CIT0012","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1200\/JCO.2000.18.18.3247","article-title":"Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group","volume":"18","author":"Bellmunt","year":"2000","journal-title":"J Clin Oncol"},{"issue":"3","key":"2024110817081966400_CIT0013","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/cncr.27751","article-title":"A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results","volume":"119","author":"Siefker-Radtke","year":"2013","journal-title":"Cancer"},{"issue":"19","key":"2024110817081966400_CIT0014","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"2024110817081966400_CIT0015","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"13","key":"2024110817081966400_CIT0016","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group","volume":"330","author":"Klahr","year":"1994","journal-title":"N Engl J Med"},{"issue":"1","key":"2024110817081966400_CIT0017","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"8476","key":"2024110817081966400_CIT0018","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"327","author":"Bland","year":"1986","journal-title":"Lancet"},{"key":"2024110817081966400_CIT0019","volume-title":"R: A Language and Environment for Statistical Comput-ing","author":"R Core Team","year":"2020"},{"issue":"6","key":"2024110817081966400_CIT0020","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.kint.2020.02.010","article-title":"Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference","volume":"97","author":"Levey","year":"2020","journal-title":"Kidney Int"},{"issue":"5","key":"2024110817081966400_CIT0021","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1445-5994.1990.tb00395.x","article-title":"Comparison of methods of assessment of renal function in patients with cancer treated with cisplatin, carboplatin or methotrexate","volume":"20","author":"Robinson","year":"1990","journal-title":"Aust N Z J Med"},{"issue":"9","key":"2024110817081966400_CIT0022","first-page":"685","article-title":"Estimation of creatinine clearance in patients with gynecologic cancer","volume":"12","author":"Tsubaki","year":"1993","journal-title":"Clin Pharm"},{"issue":"1","key":"2024110817081966400_CIT0023","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0090-8258(90)90110-7","article-title":"Correlation between measured creatinine clearance and calculated creatinine clearance in ovarian cancer patients","volume":"36","author":"Chambers","year":"1990","journal-title":"Gynecol Oncol"},{"issue":"6","key":"2024110817081966400_CIT0024","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00280-006-0339-x","article-title":"Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma","volume":"59","author":"Gerber","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2024110817081966400_CIT0025","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.kint.2021.12.010","article-title":"A prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors","volume":"101","author":"Costa E Silva","year":"2022","journal-title":"Kidney Int"},{"issue":"8","key":"2024110817081966400_CIT0026","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/annonc\/mdm011","article-title":"International Society of Geriatric Oncology. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations","volume":"18","author":"Launay-Vacher","year":"2007","journal-title":"Ann Oncol"},{"issue":"2","key":"2024110817081966400_CIT0027","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00345-013-1104-5","article-title":"The method of GFR determination impacts the estimation of cisplatin eligibility in patients with advanced urothelial cancer","volume":"32","author":"Horn","year":"2014","journal-title":"World J Urol"},{"issue":"4","key":"2024110817081966400_CIT0028","first-page":"855","article-title":"A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer","volume":"3","author":"Hussain","year":"2012","journal-title":"Oncol Lett"},{"issue":"12","key":"2024110817081966400_CIT0029","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.ejca.2012.04.002","article-title":"Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function","volume":"48","author":"Morales-Barrera","year":"2012","journal-title":"Eur J Cancer"},{"issue":"4","key":"2024110817081966400_CIT0030","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.kint.2020.06.044","article-title":"Simultaneous glomerular filtration rate determination using inulin, iohexol, and 99mTc-DTPA demonstrates the need for customized measurement protocols","volume":"99","author":"White","year":"2021","journal-title":"Kidney Int"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/11\/e1511\/60541801\/oyae160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/11\/e1511\/60541801\/oyae160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T12:08:47Z","timestamp":1731067727000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/11\/e1511\/7704481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,7,2]]},"published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae160","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,7,2]]}}}